Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic Areas
Dublin, Jan. 20, 2026 (GLOBE NEWSWIRE) -- The "Catalyst Monitor: Q1 2026 Outlook" report has been added to ResearchAndMarkets.com's offering.
This report compiles published, predictive intelligence based on interviews with key opinion leaders (KOLs) on market-moving events that are expected to occur in Q1 2026.
The report delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, top-line results, regulatory filings, PDUFA dates, and expected approvals. The report covers 13 significant catalyst events that are expected to occur in Q1 2026.
Some of the catalysts covered in the report, include approval decisions for GSK's depemokimab in asthma and sinusitis, Regenxbio's clemidsogene lanparvovec in Hunter syndrome, Omeros' narsoplimab in thrombotic microangiopathy, and more.
Additionally, experts also discuss the ongoing clinical trials with Xenon Pharmaceuticals' azetukalner for focal onset seizures, Cerevel's tavapadon for Parkinson's disease, Neumora's navacaprant for major depressive disorder (MDD), and more.
Report Scope
Reasons to Buy
Key Topics Covered:
Companies Featured
For more information about this report visit https://www.researchandmarkets.com/r/h22wta
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.